S. 495 · 115th Congress
Medical Innovation Prize Fund Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
I
SandersSponsorNo cosponsors.
This bill denies any person the exclusive right to manufacture, distribute, sell, or use a drug, a biological product, or a medication manufacturing process. The bill establishes the Fund for Medical Innovation Prizes to provide for prize payments in lieu of market exclusivity.
What it does: CRS summary · Introduced in Senate · Mar 2, 2017
Medical Innovation Prize Fund Act
This bill denies any person the exclusive right to manufacture, distribute, sell, or use a drug, a biological product, or a medication manufacturing process. The bill establishes the Fund for Medical Innovation Prizes to provide for prize payments in lieu of market exclusivity.
The Board of Trustees of the fund must award prize payments to: (1) the first person to receive approval for a medication; (2) the holder of the patent for a manufacturing process; and (3) persons or communities that contributed to the development of a rewarded medication or process through the open, nondiscriminatory, and royalty-free sharing of knowledge, data, materials, and technology.
The board must establish: (1) criteria for selecting recipients and determining the amount of prizes, and (2) independent expert advisory committees to assist it in carrying out this bill.
The board must establish, and may periodically modify, minimum levels of funding for priority research and development, including research and development regarding global neglected diseases, orphan diseases, global infectious diseases, and other global public health priorities.
The board may authorize nonprofit intermediaries to reward projects for interim research and development of products or for open source dividend prizes.
The Government Accountability Office must determine the board's effectiveness in bringing to market new medications and manufacturing processes in a cost-effective manner and in addressing society's medical needs.
The bill establishes an annual fee on health insurers to fund this bill.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Medical Innovation Prize Fund Act
Latest action (Mar 2, 2017): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Mar 2, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.